ReviewAmerican heart journal2002
High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.
Review in American heart journal, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01683656 (ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 122 citations in OpenAlex.
- Effectiveness of exergaming interventions for adults with cancer: a systematic review.Frontiers in oncology · 2026Pooled it
- Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.Vascular health and risk management · 2015Trial
- Retrospective Longitudinal Observational Study on the Long-Term Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetic Japanese Patients.Journal of clinical medicine · 2024Article
- Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders.Pharmaceutics · 2023Article
- Comparative lipid and uric acid suppressing properties of four common herbs in high fat-induced obese mice with their total phenolic and flavonoid index.Biochemistry and biophysics reports · 2021Article
- Association of apolipoprotein E gene polymorphisms with blood lipids and their interaction with dietary factors.Lipids in health and disease · 2018Article
- Article
- Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS).International journal of clinical practice · 2014 · on this mapObservational
- Dietary quality among Tehranian adults in relation to lipid profile: findings from the Tehran Lipid and Glucose Study.Journal of health, population, and nutrition · 2013Article
- Antioxidant SMe1EC2 may attenuate the disbalance of sodium homeostasis in the organism induced by higher intake of cholesterol.Molecular and cellular biochemistry · 2012Article
- Cilostazol inhibits accumulation of triglyceride in aorta and platelet aggregation in cholesterol-fed rabbits.PloS one · 2012Article
- Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events - Results of the DYSlipidemia International Study (DYSIS).Wiener klinische Wochenschrift · 2011Article
- Risk factors preceding type 2 diabetes and cardiomyopathy.Journal of cardiovascular translational research · 2010Review
- Evaluation of genetic risk scores for lipid levels using genome-wide markers in the Framingham Heart Study.BMC proceedings · 2009Article
- Lactation and changes in maternal metabolic risk factors.Obstetrics and gynecology · 2007Article
- Treatment goals for the management of lipids and inflammation for patients with coronary artery disease.Current treatment options in cardiovascular medicine · 2007Article
- Risk analysis of coronary heart diseases in Korean adults by using the National Cholesterol Education Program Adult Treatment Panel III.Journal of clinical laboratory analysis · 2007Article
- Stearoyl-coenzyme A desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma high-density lipoprotein cholesterol induced by liver X receptor activation.Molecular and cellular biology · 2006Article
- Fibrates in combination with statins in the management of dyslipidemia.Journal of clinical hypertension (Greenwich, Conn.) · 2006Review
- Genome scan for quantitative trait loci influencing HDL levels: evidence for multilocus inheritance in familial combined hyperlipidemia.Human genetics · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidemiologic and clinical trials show that elevated triglycerides and low levels of high-density lipoprotein cholesterol (HDL-C) are independent risk factors for coronary heart disease (CHD). However, adjustment for covariates frequently weakens or abolishes the predictive significance of triglycerides, whereas the evidence for HDL-C is more consistently strong. Data indicate that there is a 2% to 3% decrease in coronary risk for each 1 mg/dL increase in HDL-C, whereas the benefit of triglyceride lowering appears to occur largely in patients with the highest baseline levels. The 2001 National Cholesterol Education Program Adult Treatment Panel III (ATP III) guidelines for detecting and treating high blood cholesterol reflect our improved understanding of triglycerides and HDL as CHD risk factors. However, the guidelines place more emphasis on lowering triglycerides than on raising HDL-C by identifying non-HDL-C (ie, low-density lipoprotein cholesterol [LDL-C] + very-low-density lipoprotein cholesterol [VLDL-C]) as a secondary target of therapy. In clinical practice, VLDL-C is the most readily available measure of atherogenic triglyceride-rich remnant lipoproteins. On the basis of the available epidemiologic and clinical evidence, refinement of the NCEP guidelines to include more emphasis on raising HDL-C levels should be considered. Novel drugs are being developed that have the potential to increase HDL-C concentrations and/or improve the functionality of HDL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.